Skip to content

Effect of Thyroid Disorders in Liver Diseases

Effect of Thyroid Disorders in Metabolic Fatty Liver Changes

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06071923
Enrollment
140
Registered
2023-10-10
Start date
2024-01-01
Completion date
2025-02-28
Last updated
2023-10-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fatty Liver Disease

Brief summary

Aims of the Research 1. To detect correlation between hyperthyroidism and non alcoholic fatty liver disease (NAFLD). 2. To detect hepatic risk in subclinical and clinical hypothyroidism . 3. To detect early liver disorders in thyroid disorders using fibroscan .

Detailed description

Non alcoholic fatty liver disease (NAFLD) has been a health problem of growing significance all over the world; its prevalence is increasing in both developed and developing countries ,the overall prevalence of NAFLD worldwide was estimated to be 32.4%.prevalence increased significantly over time. considering the increasing incidence of NALAD/NASH, especially in developed and developing countries, it is anticipated that cirrhosis due to these conditions may exceed other causes of cirrhosis in a near future.. Thyroid gland is involved in energy homeostasis, lipid and carbohydrate metabolism, regulation of body weight and adipogenesis. In a clinical setting, subclinical hypothyroidism has been associated with metabolic syndrome, cardiovascular mortality and disturbance of lipid metabolism. The prevalence of hypothyroidism was reported to 16.8% among patients with NAFLD/NASH. In recent years, growing body of evidence has led to speculation on the association between NAFLD/NASH and thyroid dysfunction. Therefore, understanding the pathophysiology, risk factors and new treatment options of NAFLD/NASH should be among the priorities in the field of hepatology

Interventions

DEVICEFibroscan

Scan the liver for metabolic fatty changes

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* The study will include thyroid patients over one year duration ( age above 18 years old

Exclusion criteria

1. History of liver failure or patient known to have congenital liver disease. 2. Medications associated with weight gain . 3. Patients who have diabetes mellitus. 4. patients who already have liver disease eg; chronic viral hepatitis, liver cirrhosis. 5. Patients on antistatin.

Design outcomes

Primary

MeasureTime frameDescription
Detect correlation between hyperthyroid diseases and NASH .BaselineTest the patients of thyroid disorders for metabolic fatty liver changes

Contacts

Primary ContactTasneem Mohammed Ali, Master
Tonamohammed96@gmail.com01098704665
Backup ContactHanan Mahmoud, Prof dr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026